The company has not filed an annual or quarterly report since its Q1 FY2021 10-Q, filed Apr 30, 2021. Its latest SEC filing is a SC TO-T/A from Nov 16, 2022.
10-Q for Q1 FY2021, filed Apr 30, 2021
The sections below describe the company as of the FY2020 annual report.
Develops and sells medicines for rare diseases and serious bleeding conditions to distributors, pharmacies and hospitals.
10-K for FY2020, filed Feb 8, 2021Alexion is a global biopharmaceutical company focused on serving patients and families affected by rare diseases and devastating conditions…View ↗
As a leader in rare diseases for more than 25 years, Alexion has developed and commercializes two approved complement inhibitors to treat…View ↗
Our customers are primarily comprised of distributors, pharmacies, hospitals, hospital buying groups, and other healthcare providers. In…View ↗
Distributors, pharmacies, hospitals and other healthcare providers pay for medicines after delivery; in some countries, distributors pay when they sell the medicines to the end user.
10-K for FY2020, filed Feb 8, 2021Our principal source of revenue is product sales. Our contracts with customers generally contain a single performance obligation and we…View ↗
Our customers are primarily comprised of distributors, pharmacies, hospitals, hospital buying groups, and other healthcare providers. In…View ↗
The timing between the recognition of revenue for product sales and the receipt of payment is not significant. Our standard credit terms…View ↗
$6.1B
10-K for FY2020, filed Feb 8, 2021
$6.1B ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Net Product Sales
Sold outright
10-K for FY2020, filed Feb 8, 2021 |
100% |
Net Product Sales, FY2020
$6.1B Sources
|
Sold outright |
|
Other revenue
|
<0.1%
FY2017: 0.1%
|
Other revenue, FY2020
$800K Sources
|
Distributors and healthcare providers buy Alexion's medicines; in some cases, governments and government agencies also purchase them.
10-K for FY2020, filed Feb 8, 2021Our customers are primarily comprised of distributors, pharmacies, hospitals, hospital buying groups, and other healthcare providers. In…View ↗
Yes. It kept 10 cents of every revenue dollar as net income in FY2020 and turned 48 cents into free cash flow.
10-K for FY2020, filed Feb 8, 2021
$632.3MView ↗
10-K for FY2020, filed Feb 8, 2021
$603.4MView ↗
10-K for FY2020, filed Feb 8, 2021
$2.9BView ↗
10-Q for Q1 FY2021, filed Apr 30, 2021
$636MView ↗
10-Q for Q1 FY2021, filed Apr 30, 2021
Open tableView ↗
8-K, filed Jul 22, 2021
On July 14, 2021, AstraZeneca disclosed that the parties had received all regulatory approvals required to complete the Merger. On the…View ↗
Grew. Revenue grew 97% in 4 years, from $3.1B in FY2016 to $6.1B in FY2020, about 18% a year.
Added an acute-care medicine
The portfolio expanded to include ANDEXXA, a Factor Xa inhibitor reversal treatment for life-threatening or uncontrolled bleeding; the older marketed-products section describes complement and enzyme-replacement therapies.
10-K for FY2017, filed Feb 8, 2018 10-K for FY2020, filed Feb 8, 2021As a leader in rare diseases for more than 25 years, Alexion has developed and commercializes two approved complement inhibitors to treat…View ↗
Acute CareView ↗
Reversal of anticoagulation in patients treated with Factor Xa inhibitors when experiencing life-threatening or uncontrolled bleeding.View ↗
Added ULTOMIRIS
The latest report describes ULTOMIRIS alongside SOLIRIS as a marketed complement inhibitor, while the older marketed-products discussion focuses on SOLIRIS.
10-K for FY2017, filed Feb 8, 2018
Expanded complement treatment to NMOSD
The latest report includes NMOSD among conditions treated by an approved complement inhibitor; the older report describes treatment for PNH, aHUS and gMG.
10-K for FY2017, filed Feb 8, 2018 10-K for FY2020, filed Feb 8, 2021We are the global leader in complement inhibition and have developed and commercialize the first and only approved complement inhibitor to…View ↗
As a leader in rare diseases for more than 25 years, Alexion has developed and commercializes two approved complement inhibitors to treat…View ↗
Loading...
